Therapy Type: Immunotherapy (passive) (timeline)
Target Type: Amyloid-Related (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 1)
Company: Eli Lilly & Co.
LY2599666 is an investigational therapy of undisclosed mechanism, without preclinical information in the public literature. It is delivered by subcutaneous injection.
In December 2015, Eli Lilly started a large Phase 1 trial, comparing LY2599666 directly to solanezumab, the company's anti-Aβ antibody, in 130 study volunteers. Solanezumab is administered by way of intravenous infusion, whereas LY2599666 is injected under the skin. A multicenter trial in the United States and Japan is directly comparing these two agents to each other, on the same safety, pharmacokinetic, and plasma Aβ outcomes. The trial enrolls people who are either cognitively healthy or have a clinical diagnosis of amnestic MCI due to AD or mild to moderate Alzheimer's ascertained by a positive amyloid PET scan. The trial compares a single injection of LY2599666, a three-month course of weekly injections of LY2599666, to a three-month course of either weekly or monthly infusions of solanezumab.
No Available Further Reading